185 related articles for article (PubMed ID: 26090722)
1. Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.
Woo JK; Kang JH; Kim B; Park BH; Shin KJ; Song SW; Kim JJ; Kim HM; Lee SJ; Oh SH
Oncotarget; 2015 Sep; 6(27):24047-60. PubMed ID: 26090722
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
[TBL] [Abstract][Full Text] [Related]
3. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor suppresses the anticancer effect of irinotecan by decreasing the level of active metabolite in HepG2 cells.
Okumura M; Iwakiri T; Takagi A; Hirabara Y; Kawano Y; Arimori K
Biochem Pharmacol; 2011 Dec; 82(11):1720-30. PubMed ID: 21840303
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor (HGF), heat shock proteins (HSPs) and multidrug resistance protein (MRP) expression in co-culture of colon tumor spheroids with normal cells after incubation with interleukin-1beta (IL-1beta) and/or camptothecin (CPT-11).
Paduch R; Jakubowicz-Gil J; Niedziela P
Indian J Exp Biol; 2010 Apr; 48(4):354-64. PubMed ID: 20726333
[TBL] [Abstract][Full Text] [Related]
7. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
[TBL] [Abstract][Full Text] [Related]
8. Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors.
Mira A; Morello V; Céspedes MV; Perera T; Comoglio PM; Mangues R; Michieli P
Oncotarget; 2017 Jun; 8(24):38193-38213. PubMed ID: 28445144
[TBL] [Abstract][Full Text] [Related]
9. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
[TBL] [Abstract][Full Text] [Related]
10. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
[TBL] [Abstract][Full Text] [Related]
11. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor.
Neaud V; Faouzi S; Guirouilh J; Le Bail B; Balabaud C; Bioulac-Sage P; Rosenbaum J
Hepatology; 1997 Dec; 26(6):1458-66. PubMed ID: 9397985
[TBL] [Abstract][Full Text] [Related]
12. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
14. The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma.
Saito S; Morishima K; Ui T; Hoshino H; Matsubara D; Ishikawa S; Aburatani H; Fukayama M; Hosoya Y; Sata N; Lefor AK; Yasuda Y; Niki T
BMC Cancer; 2015 Feb; 15():82. PubMed ID: 25884729
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression.
Kanaji N; Yokohira M; Nakano-Narusawa Y; Watanabe N; Imaida K; Kadowaki N; Bandoh S
Respir Res; 2017 Jun; 18(1):118. PubMed ID: 28619066
[TBL] [Abstract][Full Text] [Related]
16. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions.
Nakamura T; Matsumoto K; Kiritoshi A; Tano Y; Nakamura T
Cancer Res; 1997 Aug; 57(15):3305-13. PubMed ID: 9242465
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
[TBL] [Abstract][Full Text] [Related]
18. Cancer Associated Fibroblast-Derived Hepatocyte Growth Factor Inhibits the Paclitaxel-Induced Apoptosis of Lung Cancer A549 Cells by Up-Regulating the PI3K/Akt and GRP78 Signaling on a Microfluidic Platform.
Ying L; Zhu Z; Xu Z; He T; Li E; Guo Z; Liu F; Jiang C; Wang Q
PLoS One; 2015; 10(6):e0129593. PubMed ID: 26115510
[TBL] [Abstract][Full Text] [Related]
19. Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts.
Fenouille N; Grosso S; Yunchao S; Mary D; Pontier-Bres R; Imbert V; Czerucka D; Caroli-Bosc FX; Peyron JF; Lagadec P
J Pathol; 2012 May; 227(1):118-29. PubMed ID: 22069124
[TBL] [Abstract][Full Text] [Related]
20. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
Liu L; Zeng W; Wortinger MA; Yan SB; Cornwell P; Peek VL; Stephens JR; Tetreault JW; Xia J; Manro JR; Credille KM; Ballard DW; Brown-Augsburger P; Wacheck V; Chow CK; Huang L; Wang Y; Denning I; Davies J; Tang Y; Vaillancourt P; Lu J
Clin Cancer Res; 2014 Dec; 20(23):6059-70. PubMed ID: 25231402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
